Treatment of Anti-MDA5 Autoantibody-Positive Juvenile Dermatomyositis Using Tofacitinib

    September 2019 in “ Brain ”
    Sara Sabbagh, Adriana A. de Jesus, SuJin Hwang … Lisa G. Rider
    Studysummary In this study, two patients with refractory juvenile dermatomyositis improved clinically and in disease activity after receiving the JAK inhibitor tofacitinib, showing potential effects in managing the condition.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on academic.oup.com →
    Discuss this study in the Community →